Universal DX key facts
as of Oct 2026- Operator of a bioinformatics and multi-omics company intended to transform cancer into a preventable and curable disease.
- Universal DX is valued at approximately $99.2M as of Oct 2026 (last reported valuation).
- It has raised $144.0M; the latest was Later Stage VC in Jan 2026.
- Notable investors include MedTech Innovator, Endeavor Catalyst, Johnson & Johnson Innovation - JLABS, Spanish Society for Technological Transformation, Longbrook Ventures — 13 tracked in total.
- Status: Privately Held (backing).
Universal DX's last reported valuation, Jan 2021. Nothing priced has surfaced since.
- ·The complete investor list: 13 names
- ·Watch Universal DX: the Monday email on marks, rounds and moves
Universal DX funding rounds
No funding rounds for Universal DX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Universal DX
13+Universal DX valuation
Universal DX's last reported valuation was $99.2 million in Jan 2021. No priced round, secondary trade or fund mark has surfaced since.
Universal DX investors
13 investors are on record for Universal DX, including MedTech Innovator, Endeavor Catalyst, Johnson & Johnson Innovation - JLABS and Spanish Society for Technological Transformation.
About Universal DX
Operator of a bioinformatics and multi-omics company intended to transform cancer into a preventable and curable disease. The company combines proprietary tools with machine learning algorithms to offer minimally invasive, blood-based tests that can detect the disease in its earliest stages and forms, enabling doctors to have tools to achieve accuracy in early cancer detection.
- Sector
- Healthcare
- HQ
- Seville, Spain
- Founded
- 2012
- Employees
- 110
- Website
- universaldx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.